den Heijer M, Brouwer I A, Bos G M, Blom H J, van der Put N M, Spaans A P, Rosendaal F R, Thomas C M, Haak H L, Wijermans P W, Gerrits W B
Department of Hematology, Leyenburg Hospital, The Hague, The Netherlands.
Arterioscler Thromb Vasc Biol. 1998 Mar;18(3):356-61. doi: 10.1161/01.atv.18.3.356.
Hyperhomocysteinemia is a risk factor for atherosclerosis and thrombosis and is inversely related to plasma folate and vitamin B12 levels. We assessed the effects of vitamin supplementation on plasma homocysteine levels in 89 patients with a history of recurrent venous thrombosis and 227 healthy volunteers. Patients and hyperhomocysteinemic (homocysteine level >16 micromol/L) volunteers were randomized to placebo or high-dose multivitamin supplements containing 5 mg folic acid, 0.4 mg hydroxycobalamin, and 50 mg pyridoxine. A subgroup of volunteers without hyperhomocysteinemia was also randomized into three additional regimens of 5 mg folic acid, 0.5 mg folic acid, or 0.4 mg hydroxycobalamin. Before and after the intervention period, blood samples were taken for measurements of homocysteine, folate, cobalamin, and pyridoxal-5'-phosphate levels. Supplementation with high-dose multivitamin preparations normalized plasma homocysteine levels (< or = 16 micromol/L) in 26 of 30 individuals compared with 7 of 30 in the placebo group. Also in normohomocysteinemic subjects, multivitamin supplementation strongly reduced homocysteine levels (median reduction, 30%; range, -22% to 55%). In this subgroup the effect of folic acid alone was similar to that of multivitamin: median reduction, 26%; range, -2% to 52% for 5 mg folic acid and 25%; range, -54% to 40% for 0.5 mg folic acid. Cobalamin supplementation had only a slight effect on homocysteine lowering (median reduction, 10%; range, -21% to 41%). Our study shows that combined vitamin supplementation reduces homocysteine levels effectively in patients with venous thrombosis and in healthy volunteers, either with or without hyperhomocysteinemia. Even supplementation with 0.5 mg of folic acid led to a substantial reduction of blood homocysteine levels.
高同型半胱氨酸血症是动脉粥样硬化和血栓形成的一个危险因素,且与血浆叶酸和维生素B12水平呈负相关。我们评估了维生素补充剂对89例有复发性静脉血栓形成病史的患者及227名健康志愿者血浆同型半胱氨酸水平的影响。患者及高同型半胱氨酸血症(同型半胱氨酸水平>16微摩尔/升)志愿者被随机分为安慰剂组或高剂量多种维生素补充剂组,后者含有5毫克叶酸、0.4毫克羟钴胺素和50毫克吡哆醇。一个无高同型半胱氨酸血症的志愿者亚组也被随机分为另外三种方案组,分别补充5毫克叶酸、0.5毫克叶酸或0.4毫克羟钴胺素。在干预期前后,采集血样以测定同型半胱氨酸、叶酸、钴胺素和磷酸吡哆醛-5'-磷酸水平。与安慰剂组30人中7人相比,高剂量多种维生素制剂补充使30人中26人的血浆同型半胱氨酸水平恢复正常(≤16微摩尔/升)。同样在同型半胱氨酸水平正常的受试者中,多种维生素补充剂也显著降低了同型半胱氨酸水平(中位数降低30%;范围为-22%至55%)。在该亚组中单独叶酸的效果与多种维生素相似:5毫克叶酸时中位数降低26%;范围为-2%至52%,0.5毫克叶酸时中位数降低25%;范围为-54%至40%。钴胺素补充对降低同型半胱氨酸水平仅有轻微作用(中位数降低10%;范围为-21%至41%)。我们的研究表明,联合维生素补充剂能有效降低静脉血栓形成患者及健康志愿者(无论有无高同型半胱氨酸血症)的同型半胱氨酸水平。即使补充0.5毫克叶酸也能使血液同型半胱氨酸水平大幅降低。